Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The QUAZAR trial demonstrated that oral azacitidine significantly improves overall survival (24.7 months vs. 14.8 months for placebo) and relapse-free survival (10.2 months vs. 4.8 months for placebo) in adults with AML who cannot undergo stem cell transplantation. This evidence is derived from a Phase 3 RCT, which supports a clear clinical advantage over standard care.
Cost effectiveness
The cost-effectiveness estimates for oral azacitidine are within NICE’s acceptable range for end-of-life treatments, with ICERs slightly above £30,000 per QALY gained. The committee found the model robust after addressing uncertainties, supporting its marginal cost-effectiveness.
Quality of life
The committee acknowledged that oral azacitidine improves quality of life by allowing treatment at home, reducing hospital visits, and potentially extending life expectancy. However, specific HRQoL data post-relapse were not fully captured in the QUAZAR trial, leading to a moderate rating.
Supporting Domains
Safety and Adverse Effects
Oral azacitidine has a favorable safety profile, with adverse events primarily being mild to moderate. The committee noted that serious adverse events were rare, indicating good tolerability compared to existing therapies.
Comparator Selection
The main comparator was placebo plus best supportive care, which is appropriate for the population studied. However, the exclusion of low dose cytarabine and subcutaneous azacitidine as comparators raised concerns about the completeness of the evidence base.
Patient Population and Subgroups
The QUAZAR trial included a representative population of adults with AML in complete remission who cannot undergo stem cell transplantation. The committee noted that the trial’s EU-subgroup data were generalizable to UK clinical practice.
Care Pathway Integration
Oral azacitidine can be integrated into existing care pathways with minimal disruption, as it allows for home administration and does not require new infrastructure or extensive training for healthcare providers.
Resource Use and Cost Implications
The implementation of oral azacitidine is expected to have a manageable budget impact, as it provides a new treatment option for a population with limited alternatives, potentially leading to cost savings in hospitalizations.
Evidence Quality and Robustness
The evidence is based on a well-conducted Phase 3 RCT with low risk of bias and robust data. The committee found the trial’s design and execution to be strong, supporting the reliability of the findings.
Uncertainty, Sensitivity, and Broader Impacts
While there are some uncertainties regarding long-term benefits and the impact of treatment effect waning, the overall context of unmet need and the potential to address equity issues in treatment access support a moderate rating.
